ABSTRACT BACKGROUND Catheter ablation of atrial fibrillation using thermal energies such as radiofrequency or cryothermy is
to all thermal energies, including radiofrequency energy, cryothermy, laser, ultrasound, and microwave (even x-ray or proton beam therapy), is their propensity to ablate all tissues indiscriminately. There is a zero-sum relationship between safety and efficacy-greater efficacy is achieved with more ablation but at the expense of safety, and vice versa.
In contrast, pulsed field ablation (PFA) is a nonthermal ablative modality in which ultrarapid (<1 s) electrical fields are applied to target tissue. This destabilizes cell membranes by forming irreversible nanoscale pores and leakage of cell contents, culminating in cell death (3) (4) (5) (6) . Importantly, various tissues have specific characteristic threshold field strengths that induce necrosis (7) (8) (9) . Indeed, PFA is used to treat solid tumors that are unresectable because of close proximity to major blood vessels or nerves, as these structures are relatively resistant to pulsed electric fields. Similarly, PFA seems uniquely suited for cardiac ablation, because cardiomyocytes have among the lowest threshold values of any tissue (7) . This myocardial sensitivity could potentially limit collateral damage of nontarget tissue such as the esophagus and phrenic nerve.
Beyond safety, it is well-appreciated that the primary mechanism for AF recurrence after conventional ablation procedures is electrical PV reconnection over time-because of incomplete lesion transmurality and/or contiguity. The frequency of all PVs durably isolated per patient has been reported to range from w20% to 80%. But unlike other energies, multiple parameters can be fine-tuned with PFA, resulting in different lesion profiles and efficacy. We previously reported that catheter-based PFA using a monophasic waveform could acutely isolate PVs;
however, this first-generation waveform was used in only 15 patients, and there was no safety or efficacy follow-up data available (10) . Herein, in 2 first-inhuman clinical trials of paroxysmal AF, we studied the extended outcomes of the monophasic waveformtreated patients, as well as in a substantially larger cohort treated with next-generation biphasic PFA waveforms. We assessed both the long-term safety of PFA and the durability of electrical PV isolation using protocol-mandated invasive remapping procedures. Table 2 .
METHODS
PFA SYSTEM. The PFA system has 3 components: a custom generator that delivers a high-voltage pulsed field waveform over multiple channels (while the unit is programmable with various waveform and bipolar electrode pairing options, for convenience of waveform iteration, the waveform is fixed in a given clinical version), a PFA catheter, and a 13-F steerable sheath (Farapulse). The IMPULSE and PEFCAT feasibility protocols were designed to optimize PFA by allowing flexibility in the delivered dose and waveform. The therapeutic waveform is structured as a hierarchical set of microsecond-scale pulses in bipolar fashion across electrodes, with ablation delivery synchronized to pacing over a small number of heartbeats (4 to 10 heartbeats). The ablation protocol underwent consecutive evolutionary modifications: from monophasic to biphasic pulses, and then optimizing the biphasic waveform morphology and pulse sequence composition (Online Table 3 ). ENDPOINTS. The endpoints for IMPULSE and PEF-CAT are similar (Online Table 1 ). The primary safety endpoint was a composite of major safety events including cardiac tamponade, stroke or transient ischemic attack (TIA), diaphragmatic paralysis, PV stenosis, heart block, atrioesophageal fistula, myocardial infarction, and death. In IMPULSE and PEFCAT, the endpoint included events that occurred within 7 and 30 days post-procedure, respectively.
The primary feasibility/effectiveness endpoint in both trials was the proportion of subjects with all PVs electrically isolated with PFA alone.
There were also several secondary safety end- Values are mean AE SD, n (%), or n. The mean fluoroscopy time was 13.1 AE 7.6 min ( Table 2 ). The mean total skin-to-skin procedure time Table 4 Furthermore, brain magnetic resonance imaging was performed in 13 patients ( Table 4) . They were negative for lesions using both diffusion-weighted imaging and fluid attenuated inversion recovery imaging, thus revealing no evidence of silent cerebral ischemic events.
At the end of the index procedure, in all patients, the integrity of the phrenic nerve was verified by phrenic capture during pacing from the superior vena cava or by observing diaphragm movement during spontaneous respiration (Table 4) . Furthermore, fluoroscopy was performed in those patients presenting for the remapping procedures (n ¼ 52), revealing no diaphragmatic impairment in any patient.
Beyond the absence of clinical PV stenosis, the PV caliber was studied using 2 approaches. During invasive remapping, there was no evidence of PV stenosis upon catheter-based electroanatomic mapping Table 5) .
DISCUSSION
In a combined analysis of 2 first-in-human studies, we evaluated the feasibility, safety, and efficacy of pulsed field ablation to electrically isolate pulmonary veins in patients with paroxysmal atrial fibrillation.
The rate of primary safety events was low (1.2%), and due to a case of pericardial tamponade. There were no subsequent primary adverse events during follow-up. Somewhat unique to PFA: 1) the electric field strength thresholds required for myocardial cell death are among the lowest of any tissue type (Online Figure 2) ; and 2) because the mechanism of cell death is nonthermal, the propensity for collateral damage appears to be lower than with thermal energy sources (7) (8) (9) . Preclinical experiments have shown that there is no significant PV stenosis, phrenic nerve injury, or esophageal injury with PFA delivered even directly atop those structures (13) (14) (15) . This tissue-selective property of PFA was confirmed in the present study.
Despite using no esophageal protection strategy, there was no evidence of esophageal necrosis by either CMR (delayed enhancement or T 2 imaging) or endoscopy. Similarly, the proximity of the phrenic nerve to the right superior PV was evidenced by diaphragmatic capture during PFA applications, but there was no evidence of phrenic paresis, let alone palsy. Finally, the absence of thermal coagulative necrosis translated to no PV stenosis or even PV narrowing, and no evidence of thrombus leading to stroke. The overall number of patients with negative brain magnetic resonance imaging was not large, but it was sufficient to verify that microbubble formation during PFA is not physiologically relevant (similar to the eruption of spontaneous echocardiographic contrast observed upon cryoballoon thawing).
The rates of atrioesophageal fistula, phrenic nerve injury, stroke/TIA, and PV stenosis requiring intervention following radiofrequency or cryoballoon ablation are not particularly frequent: 0.04% to 0.15%, 2.7%, 0.94%, and 0.29% respectively; however, they are associated with significant morbidity and mortality (1, (16) (17) (18) . But, unlike thermal energy sources, which have a predictable dose-safety relationship, PFA fundamentally alters this calculus because safety is maintained through a wide range of doses.
Of course, these favorable safety data must be Pulsed Field Ablation for AF 100%. For comparison, no thermal ablation technology has been able to demonstrate such a low rate of PV reconnection; indeed, the published rates of durable isolation on a per-vein and per-patient basis have ranged from 51% to 93% and 21% to 79%, respectively (Online Table 6 ). It should also be noted that protocols that mandate invasive remapping procedures regardless of arrhythmia recurrence are notoriously difficult to conduct. Despite this complexity of study design, the number of patients
we enrolled exceeded what most previous remapping studies were able to enroll (Online Table 6 ). (Top) Thermal ablation using radiofrequency or cryoballoon catheters damages all tissue types indiscriminately, potentially damaging adjacent structures such as the phrenic nerve and esophagus. Conversely, pulsed field ablation (PFA) was shown to preferentially affect myocardial tissue, thus sparing these adjacent structures.
(Bottom) The durability of pulmonary vein (PV) isolation can be determined by invasive remapping at w3 months post-ablation. In prior studies using radiofrequency (red bars), laser balloon (light blue bar) or cryoballoon (dark blue bars) catheters, all PVs remained durably isolated in <80% of patients. Conversely, using the optimized Biphasic 3 waveform, 100% of PFA patients had all PVs durably isolated (purple bar) (see also Online Table 6 ablation should be conducted in the future. Due to differences in regional regulatory approval policies, 2 similar but separate studies were conducted and subsequently combined for this analysis. The median follow-up duration was only 120 days; however, it is arguable that the durable PV isolation data is a better predictor of long-term success than even 1-year clinical outcome data. Also, the changes to the pulse waveform over the course of the trials were not pre-specified.
The PFA catheter was only designed for PV isola- 
CONCLUSIONS
We demonstrate that in patients with paroxysmal atrial fibrillation, PFA rapidly and efficiently isolates PVs with a degree of tissue selectivity and a safety profile heretofore not described for cardiac ablation.
Furthermore, invasive electrophysiological studies demonstrated that PFA can achieve a high degree of durable PV isolation. Twitter: @jskoruth, @SriniDukkipati.
